India’s Supreme Court has recently denied an appeal by the Swiss pharmaceutical company Novartis, which was seeking patent protection for its cancer drug, Glivec.  India’s Commerce and Industry Minister, Anand Sharma, claims that it’s necessary to strike a balance between the social obligation to provide affordable medicine and supporting innovation in research and development through providing patent protection.